Skip to main content

Further GMP expansion in peptides for CordenPharma

CordenPharma has announced the approval of a long-term expansion initiative “to further increase our flexibility, efficiency and ultimately, cost-effective production” at its solid-phase peptide synthesis (SPPS) in Boulder, Colorado. This follows the installation of an extra-large 3,000L SPPS vessel at the site earlier this year in response to growing demand for peptide APIs.

The facility, which was formerly owned by Roche, already has a 10,000-litres SPPS vessel and a 100 cm high-pressure reverse phase purification column. It is claimed to have the largest capacity of any peptide API facility, as well as being able to produce peptide APIs from laboratory-scale to commercialisation at tonne-scale.

In the first phase of the new expansion, customised automated synthesiser production lines will be installed to support GMP manufacture in the low to mid-kg scale range. The company added that “special emphasis on design will further harmonise our network and enable a seamless tech transfer” process from its centre of excellence for peptide process development and non-GMP manufacturing at Frankfurt, Germany.

CordenPharma had earlier announced an unspecified investment at this site to increase lab space by 25% and add a dedicated explosionproof area, supported by a tank farm, which “will allow for the introduction of regular solvents, as well as compatibility with our green peptide manufacturing”. This should be complete in Q3 2021.

Add new comment

Plain text

  • No HTML tags allowed.
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.